Free Newsletter
Researchers on trail of cheaper, easier HPV vaccine
Researchers at Johns Hopkins have come up with a synthetic vaccine for HPV that can be delivered as a nasal spray. The current vaccine, Gardasil, is delivered via three injections.
HPV is a commonly transmitted disease that can cause cervical cancer. Gardasil guards against four strains of HPV responsible for the lion's share of cervical cancer cases. The researchers want to develop a vaccine that will guard against all strains of HPV.
"What we have done is to try to develop a completely synthetic vaccine that would induce antibodies that would neutralize and protect against a whole range of these cancer-causing strains," Richard B.S. Roden, an associate professor of pathology, gynecology and obstetrics, and oncology at Johns Hopkins University, tells Health Day. And by making it chemically rather than through a biologic process the researchers say they can make the vaccine cheaper as well.
In a study involving mice, the researchers say a synthetic vaccine worked to protect the animals against two strains of HPV. The mice were bred with T helper cells known to assist the immune system.
- read the article from Health Day
Related Articles:
Merck's Gardasil OK'd for pricey rollout. Gardasil report
Brits to vaccinate schoolgirls against HPV. Vaccine report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




